-$0.10 EPS Expected for Strongbridge Biopharma plc (NASDAQ:SBBP) This Quarter


Share on StockTwits

Equities analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to report earnings of ($0.10) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Strongbridge Biopharma’s earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.13). Strongbridge Biopharma reported earnings of ($0.19) per share in the same quarter last year, which would indicate a positive year over year growth rate of 47.4%. The company is expected to report its next earnings results on Wednesday, May 5th.

According to Zacks, analysts expect that Strongbridge Biopharma will report full-year earnings of ($0.37) per share for the current financial year, with EPS estimates ranging from ($0.45) to ($0.29). For the next year, analysts forecast that the company will report earnings of ($0.20) per share, with EPS estimates ranging from ($0.33) to ($0.06). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last posted its quarterly earnings results on Tuesday, March 2nd. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.01. Strongbridge Biopharma had a negative return on equity of 65.85% and a negative net margin of 149.79%. The company had revenue of $8.23 million for the quarter, compared to analysts’ expectations of $8.14 million.

Several equities analysts recently issued reports on SBBP shares. Zacks Investment Research upgraded Strongbridge Biopharma from a “sell” rating to a “hold” rating in a research report on Wednesday, March 10th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Strongbridge Biopharma in a report on Thursday, March 4th.

A number of hedge funds have recently bought and sold shares of the stock. American International Group Inc. lifted its stake in Strongbridge Biopharma by 20.5% in the 4th quarter. American International Group Inc. now owns 25,591 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 4,352 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Strongbridge Biopharma by 3.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 137,987 shares of the biotechnology company’s stock valued at $336,000 after buying an additional 4,373 shares in the last quarter. Susquehanna International Group LLP lifted its stake in Strongbridge Biopharma by 33.5% in the 4th quarter. Susquehanna International Group LLP now owns 17,875 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 4,484 shares in the last quarter. Rhumbline Advisers raised its holdings in Strongbridge Biopharma by 18.3% in the 4th quarter. Rhumbline Advisers now owns 29,736 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 4,595 shares during the last quarter. Finally, HighVista Strategies LLC raised its holdings in Strongbridge Biopharma by 23.1% in the 4th quarter. HighVista Strategies LLC now owns 28,432 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 5,332 shares during the last quarter. 58.27% of the stock is currently owned by hedge funds and other institutional investors.

Shares of SBBP traded up $0.01 during midday trading on Thursday, reaching $2.55. 13,302 shares of the stock were exchanged, compared to its average volume of 979,997. The business’s 50-day moving average price is $2.74 and its 200 day moving average price is $2.73. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.51 and a quick ratio of 4.45. Strongbridge Biopharma has a twelve month low of $1.87 and a twelve month high of $4.63. The company has a market capitalization of $172.24 million, a price-to-earnings ratio of -2.79 and a beta of 1.91.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis.

Recommended Story: Cost of Debt

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.